What effects can amantadine have in a patient with Glasgow Coma Scale 10, acute kidney injury (serum creatinine 5 mg/dL) and anuria (no urine output)?

Amantadine is Absolutely Contraindicated in This Patient and Must Be Avoided or Immediately Discontinued

In a patient with GCS 10, severe AKI (creatinine 5 mg/dL), and anuria, amantadine poses extreme risk of life-threatening neurotoxicity and death due to drug accumulation. This patient has essentially zero renal clearance, and amantadine is 90% renally excreted unchanged—creating a perfect storm for toxic accumulation 1.

Critical Toxicity Risks

Central Nervous System Toxicity

Amantadine accumulation in renal failure causes severe CNS toxicity that will worsen this patient's already compromised mental status (GCS 10):

• Delirium, hallucinations, and psychotic reactions 1
• Seizures (particularly dangerous given existing altered consciousness) 1
• Coma and further depression of consciousness 1
• Agitation, aggressive behavior, confusion, and disorientation 1

The FDA label explicitly warns that deaths have been reported from drug accumulation in patients with renal impairment who received higher than recommended doses for their renal function level 1. With a creatinine of 5 and no urine output, this patient has essentially no drug clearance capacity.

Cardiovascular and Respiratory Complications

Drug overdose from accumulation causes:

• Cardiac arrhythmias, tachycardia, and hypertension 1
• Pulmonary edema and ARDS 1
• These complications are particularly catastrophic in an already critically ill patient

Renal Toxicity Amplification

The FDA label documents that renal insufficiency can occur from amantadine overdose 1, potentially worsening the existing AKI. Additionally, amantadine's anticholinergic effects cause urinary retention 2, which could contribute to obstructive renal failure 2.

Pharmacokinetic Disaster

Amantadine clearance is directly proportional to renal function. In patients with creatinine clearance <50 mL/min/1.73m², dosage reduction is mandatory 3, 4, 3, 4, 3. Your patient with creatinine 5 and anuria has essentially zero clearance.

The evidence shows:

• Normal renal clearance: 10,965 mL/h
• Severe renal impairment: drops to 2,618 mL/h 5
• Anuria: effectively zero clearance

With a half-life of 17±4 hours in normal patients 1, the half-life in anuric patients extends dramatically, leading to exponential accumulation with each dose.

Clinical Evidence of Toxicity in Renal Failure

Recent case reports demonstrate the severity:

• A dialysis patient developed acute mania, incoherent speech, and vivid visual hallucinations requiring 5 consecutive days of combined hemoperfusion and hemodialysis for clearance 6
• A patient with declining renal function developed Holmes-like tremor, gait instability, and dysarthria with plasma amantadine concentration of 3,935 ng/mL (35 hours post-dose) 7
• Patients with mild renal dysfunction developed hallucinations, myoclonus, and aspiration pneumonia on standard doses 8

Blood levels of 4,783 ng/dL have been documented in toxicity cases 8, and even with "mild" renal impairment, toxic symptoms emerge rapidly 9.

Management Algorithm

If Patient Is Currently on Amantadine:

1. STOP IMMEDIATELY - do not give another dose
2. Initiate urgent hemodialysis (though hemodialysis contributes minimally to clearance 3, it's the only option available)
3. Consider hemoperfusion combined with hemodialysis for enhanced clearance 6
4. Monitor for seizures - have anticonvulsants ready 1
5. Cardiac monitoring for arrhythmias 1
6. Acidify urine if any output returns (increases excretion rate) 1
7. Measure plasma amantadine concentration if available 7, 8

If Considering Amantadine:

DO NOT START - there is no safe dose in anuria. The guidelines are explicit: dosage reduction is required for creatinine clearance <50 mL/min 3, 4, 3, 4, 3, and your patient has essentially zero clearance.

Critical Pitfall

The most dangerous pitfall is assuming "standard" or even "reduced" doses are safe. Even single doses accumulate to toxic levels when there is no renal clearance. The anticholinergic effects (dry mouth, urinary retention, constipation) 1 may mask early toxicity signs, and by the time CNS symptoms appear, significant accumulation has occurred.

The combination of existing altered mental status (GCS 10) and amantadine's CNS effects creates diagnostic confusion and delays recognition of toxicity—potentially leading to the fatal outcomes documented in the FDA label 1.